#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Extra-osseous Ewing's sarcoma Epidermolysis bullosa Kidney transplant rejection Glomerulonephritis Systemic lupus erythematosus Immune-mediated myositis Leiomyosarcoma Sexually transmitted disease Fatty acid oxidation disorder Obliterative bronchiolitis Hyperchylomicronaemia Hereditary hypophosphataemic rickets Mixed-type liposarcoma Dupuytren's contracture Small for dates baby More trials…

    Learn about Rare Diseases

    Adrenogenital syndrome – Diagnostics Isodicentric chromosome 15 syndrome – Diagnostics Brain stem glioma – Diagnostics Mast cell activation syndrome Leiomyosarcoma – Basic Information Systemic sclerosis pulmonary – Basic Information Lymphatic malformation – Life with Disease Retinoblastoma – Basic Information Marginal zone lymphoma refractory Anaplastic thyroid cancer – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lysine Hydrochloride Englumafusp Alfa Gentamicin Cefazolin Sodium Eptacog Alfa (Activated) Ht-29-B Zolbetuximab Mannitol Citalopram Hydrochloride Autogene Cevumeran Rebisufligene Etisparvovec Gadoquatrane Tofogliflozin L-Histidine Hydrochloride Ocrelizumab Phosphocreatine Sodium YL201 L-ALANINE Tx200-Tr101 Pd01B More therapies…

    Learn about Your Condition

    Device related infection Renal failure Menopause Alpha-1 antitrypsin deficiency Oropharyngeal cancer Immunosuppression Post-traumatic headache Fabry's disease Fontan procedure Embolic stroke Hip arthroplasty Coronary artery disease Osteosarcoma recurrent Vulvar dysplasia Pneumonia bacterial More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Koranyi National Institute For Pulmonology

Koranyi National Institute For Pulmonology

Koranyi Frigyes Ut 1, Budapest, 1121, Hungary

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    • Non-small cell lung cancer stage IIIB
    Investigated Drugs:
    • Repotrectinib
    • Crizotinib
    Austria France Germany Greece Hungary Italy +4

  • Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Boserolimab
    • Mk-0482
    • Mk-4830
    Hungary Italy Poland Spain

  • Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria France Germany Hungary Italy The Netherlands +4

  • Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Datopotamab Deruxtecan
    Austria Belgium Czechia France Germany Greece +7

  • Study Comparing Subcutaneous Pembrolizumab with Hyaluronidase to Intravenous Pembrolizumab and Chemotherapy for First-line Treatment of Metastatic Non-Small Cell Lung Cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Glatiramer Acetate
    • Filgrastim
    • Carboplatin
    France Hungary Poland Romania Spain

  • Study on the Effectiveness and Safety of NT 201 Injections for Adults with Chronic Neuropathic Pain from Postherpetic Neuralgia or Nerve Injury

    Not recruiting

    2 1 1
    Investigated Drugs:
    • Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
    • Paracetamol
    Bulgaria France Germany Hungary Poland Spain

  • Study on Trilaciclib and Topotecan for Patients with Extensive Stage Small Cell Lung Cancer

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Topotecan
    • Trilaciclib Dihydrochloride Dihydrate
    • Glucose Monohydrate
    Austria Belgium Bulgaria Germany Greece Hungary +2

  • Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Non-small cell lung cancer
    Investigated Drugs:
    • Lenvatinib
    • Pembrolizumab
    France Germany Greece Hungary Italy Portugal +1

  • Study comparing tarlatamab with topotecan in patients with relapsed small cell lung cancer after first-line chemotherapy

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Ammonium Chloride
    • Topotecan
    • Dexamethasone
    Austria Belgium Czechia Denmark France Germany +9

  • Study on Vixarelimab for Patients with Idiopathic Pulmonary Fibrosis and Systemic Sclerosis-Associated Interstitial Lung Disease

    Not recruiting

    2 1
    Investigated Diseases:
    • Idiopathic pulmonary fibrosis
    • Systemic sclerosis pulmonary
    Investigated Drugs:
    • Vixarelimab
    Belgium France Germany Greece Hungary Italy +2
Previous Page
1 … 6 7 8 9
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!